Companies Partner to Automate Key Steps in High-Throughput Single-Cell Multiomics Experiments

BD and Hamilton Collaborate to Develop Automated Applications and Robotics-Compatible Reagent Kits

FRANKLIN LAKES, N.J., January 23, 2024

In a groundbreaking partnership, BD (Becton, Dickinson and Company) and Hamilton, renowned leaders in medical technology and laboratory automation, respectively, have joined forces to create automated applications and robotics-compatible reagent kits. This collaboration aims to revolutionize single-cell multiomics experiments by enhancing standardization, reducing human error, and enabling greater throughput.

Key Points:

• Automated applications and robotics-compatible reagent kits are in development to streamline single-cell multiomics experiments.


• The partnership between BD and Hamilton seeks to improve standardization, reduce human error, and increase throughput.


• The BD Rhapsody™ Single-Cell Analysis Library Preparation Reagent Kits will be compatible with the Hamilton Microlab® NGS STAR™ robotic liquid-handling platform.


• NGS library preparation, a critical step in single-cell multiomics experiments, will be automated, enabling more researchers to conduct larger scale studies with confidence.

Enhancing Single-Cell Multiomics Experiments through Automation

Single-cell multiomics experiments involve analyzing various molecular layers within individual cells, providing a deeper understanding of cellular heterogeneity and disease mechanisms. However, a crucial step in these experiments, next-generation sequencing (NGS) library preparation, can be time-consuming, labor-intensive, and prone to human error.

This collaboration between BD and Hamilton aims to address these challenges by automating NGS library preparation using robotics. By integrating Hamilton’s Microlab® NGS STAR™ robotic platform with BD’s Rhapsody™ Single-Cell Analysis Library Preparation Reagent Kits, researchers can automate critical steps such as pipetting and thermal cycling. This automation will enhance reproducibility, reduce the risk of contamination, and enable faster sample processing, allowing researchers to conduct larger scale single-cell multiomics studies with greater confidence.

Quotes from Key Executives

“Multiomics-based assays are increasingly used in fields like oncology and immunology to investigate cellular information and gain insights into health and disease. Ensuring reproducible results is essential, and by integrating Hamilton’s robotic technology into our portfolio, BD continues to drive automation in single-cell multiomics,” stated Steve Conly, worldwide president at BD Biosciences.

Matt Hamilton, Vice CEO at Hamilton, added, “Through this collaboration, we aim to provide researchers with a comprehensive solution that minimizes biases and increases throughput, enabling them to achieve reliable results. As single-cell multiomics becomes more widely adopted, automated solutions for high-throughput experiments will accelerate potentially life-changing discoveries.”

Phased Release of BD Rhapsody™ Single-Cell Analysis Library Preparation Reagent Kits and Hamilton Microlab® NGS STAR™ Applications

The BD Rhapsody™ Single-Cell Analysis Library Preparation Reagent Kits and Hamilton Microlab® NGS STAR™ applications will be developed and released in phases starting in 2024. This phased approach will ensure that the integrated solution meets the evolving needs of researchers and delivers the highest level of performance and reliability.

About BD

BD is a leading global medical technology company committed to improving medical discovery, diagnostics, and care delivery. With a passion for enhancing patient outcomes and clinical processes, BD develops innovative technology, services, and solutions that empower clinicians, laboratory scientists, and researchers worldwide. The company’s extensive portfolio includes products for blood collection, specimen management, infectious disease testing, cell analysis, and diabetes management. BD collaborates closely with healthcare organizations to address global health challenges, improve safety, and increase access to healthcare.

Media and Investor Contacts

• Media Contact: Troy Kirkpatrick, VP, Public Relations, 858.617.2361, [email protected]


• Investor Contact: Adam Reiffe, Sr. Director, Investor Relations, 201.847.6927, [email protected]

Disclaimer

This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those projected in the forward-looking statements. The companies assume no obligation to update or revise the forward-looking statements in this press release.

Call to Action

Don’t miss out on this groundbreaking collaboration! Stay tuned for updates on the release of the BD Rhapsody™ Single-Cell Analysis Library Preparation Reagent Kits and Hamilton Microlab® NGS STAR™ applications. Together, these companies are revolutionizing single-cell multiomics experiments. Contact BD or Hamilton today to learn more and reserve your spot at the forefront of scientific discovery!